首页 | 官方网站   微博 | 高级检索  
     

口服抗凝剂在非瓣膜性房颤伴慢性肾功能不全患者中的应用进展
引用本文:李欣,刘璐,柳志红,赵智慧,罗勤,赵青.口服抗凝剂在非瓣膜性房颤伴慢性肾功能不全患者中的应用进展[J].协和医学杂志,2022,13(2):302-307.
作者姓名:李欣  刘璐  柳志红  赵智慧  罗勤  赵青
作者单位:1.国家心血管病中心 中国医学科学院阜外医院呼吸与肺血管疾病诊治中心, 北京 100037
基金项目:北京市自然科学基金7202168中国医学科学院医学与健康科技创新工程2020-I2M-C&T-B-055
摘    要:口服抗凝剂可有效降低房颤患者的卒中风险, 但房颤伴慢性肾功能不全患者的卒中和出血风险却明显升高, 给抗凝治疗带来困难。非维生素K拮抗剂类口服抗凝剂疗效和安全性不劣于传统的抗凝剂华法林, 无需定期监测国际标准化比值, 患者依从性更好。然而, 非维生素K拮抗剂类口服抗凝剂均不同程度地通过肾脏代谢, 其在非瓣膜性房颤伴慢性肾功能不全患者中的应用尚存在争议。本文对非瓣膜性房颤伴慢性肾功能不全患者口服抗凝剂的应用进展进行综述, 以期为临床实践提供参考。

关 键 词:非瓣膜性房颤    口服抗凝剂    慢性肾功能不全
收稿时间:2021-03-08

Progress in the Application of Oral Anticoagulants in Patients with Non-valvular Atrial Fibrillation and Chronic Renal Insufficiency
Affiliation:1.Center for Respiratory and Pulmonary Vascular Disease, Fuwai Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, National Center for Cardiovascular Diseases, Beijing 100037, China2.School of Public Health, Capital Medical University, Beijing 100069, China
Abstract:Oral anticoagulants can effectively reduce the risk of stroke in patients with atrial fibrillation. However, patients with atrial fibrillation and chronic renal insufficiency have an increased risk in both stroke and bleeding, making anticoagulant therapy challenging. Compared with traditional anticoagulant warfarin, non-vitamin K antagonist oral anticoagulants are non-inferior to warfarin in efficacy and safety. They don't require routine monitoring of the international normalized ratio and have better patient compliance. However, all the non-vitamin K antagonist oral anticoagulants are partially metabolized through kidneys to a varying degree, and thus their administration in patients with atrial fibrillation and chronic renal insufficiency is controversial. This review summarizes the administration of oral anticoagulants in these patients to guide clinical practice.
Keywords:
点击此处可从《协和医学杂志》浏览原始摘要信息
点击此处可从《协和医学杂志》下载全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司    京ICP备09084417号-23

京公网安备 11010802026262号